Delaye M, Benderra MA, Deforceville L, et al. - Researchers assessed outcomes of all germ cell tumor (GCT) patients with brain metastases (BM) who underwent high-dose chemotherapy (HDCT) in their French expert center for GCT. In this retrospective analysis, there were 35 GCT cases with BM managed from 2003 to 2019 with HDCT, followed by infusions of autologous peripheral blood hematopoietic stem cells. At 2 years, overall survival was estimated to be 36.9%. A median overall survival and median progression-free survival of 12 and 8 months, respectively, was achieved. Of 35 patients included, 31 completed HDCT and 4 had treatment discontinuation post-mobilization. Favorable responses (complete, partial, or stable disease) to HDCT were exhibited by 11 patients, and death due to disease progression (17) or toxicities (3) occurred in 20 patients. According to findings, long-term survival can be achieved in GCT cases even in the presence of BM. Results indicate that HDCT can cure metachronous BM even when local treatment is not administered. Favorable responses to HDCT could be predicted by biological and radiologic responses to mobilization.